速递｜减脂又增肌！Wave Life Sciences一夜大涨147%

Core Viewpoint - Wave Life Sciences' candidate drug WVE-007 shows promising results in reducing overall and visceral fat while maintaining lean body mass, addressing key issues associated with current GLP-1 drugs [5][7][8]. Group 1: Clinical Trial Results - The INLIGHT trial, a randomized, placebo-controlled Phase I study, included over 100 participants with a BMI of 28–35 kg/m² and no other health issues [7][10]. - Data from 32 participants receiving a single 240 mg subcutaneous injection showed a 9.4% reduction in visceral fat and a 4.5% reduction in total fat after 85 days, with a 3.2% increase in lean body mass [7][8]. - The serum Activin E levels decreased by over 75% on average, indicating the potential for less frequent dosing [5][8]. Group 2: Safety and Tolerability - WVE-007 demonstrated good safety at doses up to 600 mg, with no serious adverse events reported and all treatment-related adverse reactions being mild [8]. - Clinical laboratory indicators, including lipid and liver function tests, showed no abnormal changes [8]. Group 3: Future Milestones - The company plans to release follow-up data for the 240 mg group in Q1 2026 and for the 400 mg and 600 mg groups in subsequent quarters [8]. - Future trials will explore WVE-007 in populations with higher BMI and comorbidities, both as a monotherapy and in combination with other agents [8]. Group 4: Mechanism of Action - WVE-007 targets INHBE mRNA, which is linked to fat distribution and metabolic health, with animal studies indicating that inhibiting INHBE can reduce fat cell size and improve insulin sensitivity [9]. - In combination with semaglutide, WVE-007 has shown to double weight loss effects in animal models and prevent weight regain after stopping semaglutide [9].